All In Biotech

Drug Trial Radar · NCT03744910

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients

Last checked: Nov 20, 2026Latest source record: Jul 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Title says "pivotal". Randomized with 194 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

194

Actual

Start

Oct 14, 2019

Primary completion

Apr 8, 2024

Study completion Apr 8, 2024

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
Collaborators
ICON Clinical Research
First posted
Nov 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial investigates the efficacy and safety of clazakizumab \[an anti-interleukin (IL)-6 monoclonal antibody (mAb)\] for the treatment of CABMR in recipients of a kidney transplant.

Conditions

  • Antibody-mediated Rejection

Interventions

  • ClazakizumabBiological

    Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6

  • Physiologic saline solutionDrug

    Normal saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 52 in Estimated Glomerular Filtration Rate (eGFR)Time frame: From Baseline to Week 52
  2. Number of Participants With Composite All-cause Allograft Loss or Irreversible Loss of Allograft FunctionTime frame: From Baseline to 4 years
  3. Percentage of Participants With Composite All-cause Allograft Loss or Irreversible Loss of Allograft FunctionTime frame: From Baseline to 4 years
  4. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, and Adverse Events of Special Interest (AESIs)Time frame: Up to 4 years
  5. Percentage of Participants With TEAEs, Serious TEAEs, and AESIsTime frame: Up to 4 years
  6. Number of Participants Who Tested Positive for Polyoma BK Virus (BKV), Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV)Time frame: From baseline up to 4 years
  7. Number of Participants With Abnormal Laboratory Test ResultsTime frame: Up to 4 years
  8. Percentage of Participants With Abnormal Laboratory Test ResultsTime frame: Up to 4 years
  9. Number of Participants With Clinically Significant Change in Vital Signs, Electrocardiograms (ECGs), and Physical ExaminationTime frame: Up to 4 years
  10. Number of Participants With Positive Anti-drug AntibodiesTime frame: Baseline, Weeks 12, 24, and 48
  11. Percentage of Participants With Positive Anti-drug AntibodiesTime frame: Baseline, Weeks 12, 24, and 48

Locations

142 sites in 15 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham (UAB) - University of Alabama Hospital (UAB Hospital)

    Birmingham, Alabama

  • Mayo Clinic Hospital

    Phoenix, Arizona

  • Keck Medical Center Of USC

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • UCLA Kidney Transplant Research Program

    Los Angeles, California

  • University of California Davis Medical Center

    Sacramento, California

  • California Institute of Renal Research

    San Diego, California

  • North America Research Institute

    San Dimas, California

  • California Pacific Medical Center

    San Francisco, California

  • Kaiser Permanente

    San Francisco, California

  • University of California, San Francisco Medical Center

    San Francisco, California

  • University Of Colorado Hospital - Anschutz Medical Campus

    Aurora, Colorado

  • Tampa General Medical Group

    Tampa, Florida

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • Rush University Medical Center - University Cardiovascular Surgeons

    Chicago, Illinois

  • Indiana University (IU) Health Physicians - Kidney Diseases Clinic - Medical Diagnostic Center Location

    Indianapolis, Indiana

  • Unity Point Health

    Des Moines, Iowa

  • Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • University of Louisville Research Foundation

    Louisville, Kentucky

  • Tulane University Health Sciences Center

    New Orleans, Louisiana

  • Massachusetts General Cancer Center

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Henry Ford Health System

    Detroit, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University School of Medicine - Infectious Diseases (WU ID) Clinic

    St Louis, Missouri

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Saint Barnabas Medical Center

    Livingston, New Jersey

  • Erie County Medical Center Corp.

    Buffalo, New York

  • NYU Langone Medical Center

    New York, New York

  • New York Presbyterian Hospital / Weill Cornell Medical Center

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • Duke Cancer Institute

    Durham, North Carolina

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina

  • The Ohio State University, Comprehensive Transplant Center

    Columbus, Ohio

  • University of Cincinnati

    Toledo, Ohio

  • Integris Baptist Medical Center

    Oklahoma City, Oklahoma

  • Lehigh Valley Health Network

    Allentown, Pennsylvania

  • Central Pennsylvania Transplant Foundation

    Harrisburg, Pennsylvania

  • University of Pennsylvania

    Philadelphia, Pennsylvania

Showing 40 of 142 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.